Please Wait.....
Report
Dyspepsia Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-01 I 180 Pages I EMR Inc.
Dyspepsia Market Report and Forecast 2024-2032
Dyspepsia Market Outlook
The dyspepsia market size is anticipated to grow at a CAGR of 8.4% during the forecast period of 2024-2032, driven by the growing emphasis on personalized or precision medicine in disease management across the major markets.
Dyspepsia: Introduction
Dyspepsia, commonly known as indigestion, is a condition characterized by chronic or recurrent discomfort in the upper abdomen. Symptoms may include bloating, nausea, belching, and a feeling of fullness or pain after eating. Dyspepsia can result from various causes, including gastritis, peptic ulcers, gastroesophageal reflux disease (GERD), or functional (non-ulcer) dyspepsia, where no clear cause is found. Management typically involves lifestyle modifications, dietary changes, and medications such as antacids, proton pump inhibitors, or H2-receptor antagonists to relieve symptoms.
Key Trends in the Dyspepsia Market
There's a growing trend towards increased awareness of dyspepsia symptoms and self-management practices. Over-the-counter (OTC) medications for symptom relief are in high demand, with consumers seeking immediate and accessible remedies.
As the understanding of the impact of lifestyle and diet on dyspepsia grows, there's a noticeable shift towards non-pharmacological interventions. This includes dietary modifications, stress reduction techniques, and lifestyle changes as first-line management strategies.
The market is gradually moving towards personalized treatment approaches in managing dyspepsia, especially for cases related to specific underlying conditions like H. pylori infection, GERD, or peptic ulcer disease. This trend is driven by advancements in diagnostic technologies and a better understanding of the pathophysiology of dyspepsia.
There's ongoing research and development of new pharmaceuticals targeting the underlying causes of dyspepsia and improving symptom management. This includes the development of drugs with novel mechanisms of action, such as prokinetics and agents that target the gut-brain axis.
Integration of Digital Health Solutions: Digital health technologies, including apps for diet tracking and stress management, are becoming more integrated into the management of dyspepsia. These tools help patients monitor their symptoms, manage their condition more effectively, and adhere to treatment plans.
Emerging research on the gut microbiome's role in various gastrointestinal disorders, including dyspepsia, is influencing treatment approaches. Probiotics and dietary supplements aimed at restoring gut microbiome balance are gaining popularity as complementary therapies.
Dyspepsia Market Segmentation
Market Breakup by Diagnosis
- Blood Tests
- Stool Tests
- Breath Tests
- Endoscopy
- X-Ray
- CT Scan
- Others
Market Breakup by Type
- Organic Dyspepsia
- Non-Ulcer Dyspepsia
- Drug Induced Dyspepsia
- Others
Market Breakup by Indication
- Functional Dyspepsia
- Organic Dyspepsia
Market Breakup by Treatment
- Proton Pump Inhibitors
- H2 Blockers
- Antacids
- Antibiotics
- Prokinetics
- Antidepressants
Market Breakup by Treatment Type
- Medication
- Surgery
Market Breakup by Drug Type
- Branded
- Generic
Market Breakup by Route of Administration
- Oral
- Injectable
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
- China
Dyspepsia Market Overview
In North America, the dyspepsia market is driven by a high prevalence of gastrointestinal disorders and a significant focus on digestive health. Lifestyle factors and dietary habits contribute to the demand for treatment options. The market includes a wide range of over-the-counter (OTC) and prescription medications, alongside a growing interest in probiotics and dietary supplements for symptom management. There's also an emphasis on personalized treatment approaches and non-pharmacological interventions, such as dietary modifications and stress management techniques.
Europe's market is characterized by strong healthcare systems and an emphasis on evidence-based treatments for dyspepsia. Public health initiatives aimed at improving dietary habits and reducing alcohol and tobacco consumption impact market dynamics. The availability of OTC medications is high, and there's a notable interest in natural and alternative remedies. Regulatory frameworks support rigorous testing and approval processes for new treatments, ensuring patient safety and treatment efficacy.
In Japan, the dyspepsia market reflects the country's high regard for gastrointestinal health, with a wide acceptance of both modern and traditional treatments. Japanese consumers show a strong preference for products with natural ingredients and traditional medicines alongside conventional treatments. The market is supported by advanced healthcare research, leading to the development of innovative therapeutics. Public health campaigns focusing on healthy eating and lifestyle habits also play a crucial role in managing dyspepsia symptoms.
Dyspepsia Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Bayer AG
- Mankind Pharma
- Cadila Pharmaceuticals
- Salix Pharmaceuticals
- Sanofi
- Aosaikand Pharmaceutical Co., Ltd
- Hanmi Pharm. Co.
- Lupin
- RedHill Biopharma Ltd.
- Abbott.
- GlaxoSmithKline
- Johnson&Johnson
- Eisai Co Ltd
- AstraZeneca
- Allergen Plc
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Dyspepsia Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Drug
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Dyspepsia Epidemiology Analysis - 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Dyspepsia Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.3.1 Germany Dyspepsia Epidemiology Forecast (2017-2032)
5.3.2 France Dyspepsia Epidemiology Forecast (2017-2032)
5.3.3 Italy Dyspepsia Epidemiology Forecast (2017-2032)
5.3.4 Spain Dyspepsia Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Dyspepsia Epidemiology Forecast (2017-2032)
5.4 Japan Dyspepsia Epidemiology Forecast (2017-2032)
6 Dyspepsia Market Overview - 7MM
6.1 Dyspepsia Market Historical Value (2017-2023)
6.2 Dyspepsia Market Forecast Value (2024-2032)
7 Dyspepsia Market Landscape - 7MM
7.1 Dyspepsia: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Dyspepsia Product Landscape
7.2.1 Analysis by Indication
7.2.2 Analysis by Drug Type
8 Dyspepsia Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Dyspepsia Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Dyspepsia Market Segmentation - 7MM
11.1 Dyspepsia Market by Diagnosis
11.1.1 Market Overview
11.1.2 Blood Tests
11.1.3 Stool Tests
11.1.4 Breath Tests
11.1.5 Endoscopy
11.1.6 X-Ray
11.1.7 CT Scan
11.1.8 Others
11.2 Dyspepsia Market by Type
11.2.1 Market Overview
11.2.2 Organic Dyspepsia
11.2.3 Non-Ulcer Dyspepsia
11.2.4 Drug Induced Dyspepsia
11.2.5 Others
11.3 Dyspepsia Market by Indication
11.3.1 Market Overview
11.3.2 Functional Dyspepsia
11.3.3 Organic Dyspepsia
11.4 Dyspepsia Market by Treatment
11.4.1 Market Overview
11.4.2 Proton Pump Inhibitors
11.4.3 H2 Blockers
11.4.4 Antacids
11.4.5 Antibiotics
11.4.6 Prokinetics
11.4.7 Antidepressants
11.5 Dyspepsia Market by Treatment Type
11.5.1 Market Overview
11.5.2 Medication
11.5.3 Surgery
11.6 Dyspepsia Market by Drug Type
11.6.1 Market Overview
11.6.2 Branded
11.6.3 Generic
11.7 Dyspepsia Market by Route of Administration
11.7.1 Market Overview
11.7.2 Oral
11.7.3 Injectable
11.8 Dyspepsia Market by Region
11.8.1 Market Overview
11.8.2 United States
11.8.3 EU-4 and the United Kingdom
11.8.3.1 Germany
11.8.3.2 France
11.8.3.3 Italy
11.8.3.4 Spain
11.8.3.5 United Kingdom
11.8.4 Japan
12 United States Dyspepsia Market
12.1 Dyspepsia Market Historical Value (2017-2023)
12.2 Dyspepsia Market Forecast Value (2024-2032)
12.3 Dyspepsia Market by Diagnosis
12.4 Dyspepsia Market by Indication
13 EU-4 and United Kingdom Dyspepsia Market
13.1 Dyspepsia Market Historical Value (2017-2023)
13.2 Dyspepsia Market Forecast Value (2024-2032)
13.3 Germany Dyspepsia Market Overview
13.3.1 Dyspepsia Market by Diagnosis
13.3.2 Dyspepsia Market by Indication
13.4 France Dyspepsia Market Overview
13.4.1 Dyspepsia Market by Diagnosis
13.4.2 Dyspepsia Market by Indication
13.5 Italy Dyspepsia Market Overview
13.5.1 Dyspepsia Market by Diagnosis
13.5.2 Dyspepsia Market by Indication
13.6 Spain Dyspepsia Market Overview
13.6.1 Dyspepsia Market by Diagnosis
13.6.2 Dyspepsia Market by Indication
13.7 United Kingdom Dyspepsia Market Overview
13.7.1 Dyspepsia Market by Diagnosis
13.7.2 Dyspepsia Market by Indication
14 Japan Dyspepsia Market
14.1 Dyspepsia Market Historical Value (2017-2023)
14.2 Dyspepsia Market Forecast Value (2024-2032)
14.3 Dyspepsia Market by Diagnosis
14.4 Dyspepsia Market by Indication
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Bayer AG
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Mankind Pharma
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Cadila Pharmaceuticals
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Salix Pharmaceuticals
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Sanofi
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Aosaikand Pharmaceutical Co., Ltd
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Hanmi Pharm. Co.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Lupin
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 RedHill Biopharma Ltd.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Abbott.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 GlaxoSmithKline
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Johnson & Johnson
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Eisai Co Ltd
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AstraZeneca
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Allergen Plc
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Dyspepsia Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security